Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Carbamazepine/everolimus/phenytoin interaction

Decreased therapeutic level of everolimus: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is: Drug interaction
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Fort E, et al. Everolimus therapeutic drug monitoring in cancer renal patient when drug-drug interaction is suspected: from precision to individualized treatment. Journal of Oncology Pharmacy Practice 29 (Suppl.): 20-21 abstr. 031, No. 2, Jun 2023. Available from: URL: http://doi.org/10.1177/10781552231158084 [abstract] Fort E, et al. Everolimus therapeutic drug monitoring in cancer renal patient when drug-drug interaction is suspected: from precision to individualized treatment. Journal of Oncology Pharmacy Practice 29 (Suppl.): 20-21 abstr. 031, No. 2, Jun 2023. Available from: URL: http://​doi.​org/​10.​1177/​1078155223115808​4 [abstract]
Metadaten
Titel
Carbamazepine/everolimus/phenytoin interaction
Decreased therapeutic level of everolimus: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41372-6

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Interferon-alpha

Case report

Pegaspargase

Case report

Methotrexate

Case report

Antineoplastics

Case report

Vinorelbine